Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2022 08:30 ET | Source: POINT Biopharma

POINT Biopharma to Host Investor Education Event, “Understanding the PNT2002 Phase 3 SPLASH Trial Control Arm”, on August 18, 2022

The event will prepare investors for the release of SPLASH’s lead-in cohort efficacy data later this year by providing an overview of SPLASH’s trial design. Register online today at...
May 05, 2022 09:15 ET | Source: POINT Biopharma

POINT Biopharma Confirms No Supply Shortages of 177Lu-PNT2002 for the SPLASH Trial

INDIANAPOLIS, May 05, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
April 26, 2022 08:30 ET | Source: POINT Biopharma

First European Union Patient Dosed with 177Lu-PNT2002 in the Phase 3 SPLASH Trial

POINT Biopharma’s Phase 3 SPLASH trial in pre-chemo metastatic castration-resistant prostate cancer (mCRPC) is now randomizing in the US, Canada, and Europe Sites initiated in France, Sweden,...
April 11, 2022 16:30 ET | Source: POINT Biopharma

POINT Biopharma to Present on its Pan-Cancer FAP-Alpha Targeted Program at the AACR Annual Meeting

POINT’s PNT6555 is a potent and specific inhibitor of Fibroblast Activation Protein (FAP), a phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy is planned for...
February 01, 2022 13:36 ET | Source: NextNav

NextNav Showcases APNT Backup to GNSS at European Commission's Joint Research Centre’s Trial

SUNNYVALE, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- NextNav (Nasdaq: NN) today announced that it has recently participated in the European Commission’s Joint Research Centre (JRC) alternative...
October 05, 2021 09:00 ET | Source: NextNav; Satelles, Inc.

NextNav and Satelles Collaborate to Establish an Alternative PNT Testbed in the San Francisco Bay Area

SUNNYVALE, Calif. and RESTON, Va., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NextNav and Satelles, Inc. today announced that they have partnered on an alternative positioning, navigation, and timing (PNT)...
September 28, 2021 08:00 ET | Source: POINT Biopharma

POINT Biopharma Releases New Data and Exercises Option for Best-in-Class FAP Inhibitor

Unique FAP targeting warhead combined with Actinium-225 or Lutetium-177 demonstrated complete tumor regression and long-term survival in preclinical models Initiation of a Phase 1 therapeutic...
September 23, 2021 08:00 ET | Source: POINT Biopharma

POINT Biopharma Announces Initiation of Randomization for its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

25 patient dosimetry and safety run-in met all pre-specified safety and efficacy criteria Initiated patient enrollment in Canada with additional countries to begin enrolling in 4Q21 INDIANAPOLIS,...
August 16, 2021 09:00 ET | Source: NextNav

NextNav Demonstrates World’s First GPS-Free PNT Network in Department of Homeland Security Trial

SUNNYVALE, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- NextNav, the leader in next generation GPS, announced today that it has successfully demonstrated the timing precision and resilience of its...
June 17, 2021 09:00 ET | Source: NextNav

InvenSense Barometric Sensor First to Achieve NextNav Certified Status

SUNNYVALE, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- NextNav, the leader in 3D geolocation, today announced that the ICP-10111 barometric sensor from InvenSense, a TDK group company, is the first to...